Приказ основних података о документу
Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients
dc.creator | Nikolić-Vukosavljević, Dragica | |
dc.creator | Todorović-Raković, N | |
dc.creator | Demajo, Miroslav | |
dc.creator | Ivanović, Vesna | |
dc.creator | Neskovic, B | |
dc.creator | Markicevic, M | |
dc.creator | Nešković-Konstantinović, Zora | |
dc.date.accessioned | 2018-03-01T19:36:24Z | |
dc.date.available | 2018-03-01T19:36:24Z | |
dc.date.issued | 2004 | |
dc.identifier.issn | 0262-0898 | |
dc.identifier.uri | https://vinar.vin.bg.ac.rs/handle/123456789/2869 | |
dc.description.abstract | A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta 1 (TGF-beta 1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta 1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta 1 levels when compared to plasma TGF-beta 1 levels of 6 patients with ER-positive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors status had no plasma TGF-beta 1 values overlapping with patients having positive receptors status. The TGF-beta 1 cut-off value was defined as the highest plasma TGF-beta 1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta 1 cut-off value defined low-risk subgroup of 19 patients (! 3.28 ng/ml) and high-risk subgroup of 10 patients ( GT 3.28 ng/ml) (P=0.047). Plasma TGF-beta 1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta 1 levels may be suggested. | en |
dc.rights | restrictedAccess | en |
dc.source | Clinical and Experimental Metastasis | en |
dc.subject | ER/PR status | en |
dc.subject | metastatic breast cancer | en |
dc.subject | postmenopausal patients | en |
dc.subject | survival | en |
dc.subject | TGF-beta 1 | en |
dc.title | Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients | en |
dc.type | article | en |
dcterms.abstract | Николиц-Вукосављевиц, Д; Маркицевиц, М; Несковиц-Константиновиц, З; Тодоровиц-Раковиц, Н; Демајо, М; Ивановиц, В; Несковиц, Б; | |
dc.citation.volume | 21 | |
dc.citation.issue | 7 | |
dc.citation.spage | 581 | |
dc.citation.epage | 585 | |
dc.identifier.wos | 000227724800002 | |
dc.citation.rank | M22 | |
dc.identifier.pmid | 15787095 | |
dc.identifier.rcub | https://hdl.handle.net/21.15107/rcub_vinar_2869 |
Документи
Датотеке | Величина | Формат | Преглед |
---|---|---|---|
Уз овај запис нема датотека. |